Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cassava Sciences Inc
(NQ:
SAVA
)
30.47
+0.89 (+3.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cassava Sciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
September 24, 2024
Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of its Alzheimer's drug candidate, simufilam. Here's what you need to know.
Via
Benzinga
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
September 24, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Names Rick Barry as Chief Executive Officer
September 09, 2024
Claude Nicaise, M.D. appointed Chairman of the Board
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
August 07, 2024
Via
Benzinga
Market Whales and Their Recent Bets on SAVA Options
August 06, 2024
Via
Benzinga
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
Via
Benzinga
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
August 10, 2024
Cassava Sciences has become a hot topic among traders due to its recent surge in volatility, liquidity, and overall market performance.
Via
MarketBeat
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
August 08, 2024
SAVA stock results show that Cassava Sciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
August 08, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
What's Going On With Cassava Sciences Today?
August 05, 2024
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher Monday. Here's what you need to know.
Via
Benzinga
(SAVA) - Analyzing Cassava Sciences's Short Interest
August 02, 2024
Via
Benzinga
What's Going On With Cassava Sciences Shares Today?
July 31, 2024
Cassava Sciences is set to report its second-quarter earnings on Aug. 13, with an anticipated loss of 40 cents per share, according to Benzinga Pro.
Via
Benzinga
Cassava Sciences News: Why Is SAVA Stock Trending Today?
August 06, 2024
Cassava Sciences stock is down on Tuesday even as investors take note of SAVA shares alongside a couple of pieces of news.
Via
InvestorPlace
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
August 05, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Shares Are Trading Higher Today: What You Need To Know
August 02, 2024
Cassava Sciences, Inc. (NASDAQ: SAVA) saw its stock price soar by 15.5% to $27.13, an increase of $3.64, amid rising short interest and an anticipated conference call to discuss recent developments.
Via
Benzinga
Get Your Money Out of These 3 Healthcare Stocks ASAP
August 02, 2024
Many companies in the healthcare sector have great outlooks but these healthcare stocks to sell are facing very tough challenges
Via
InvestorPlace
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
August 01, 2024
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%.
Via
Benzinga
Here's How Much $1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
July 23, 2024
Via
Benzinga
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
August 01, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday
July 31, 2024
Via
Benzinga
SmartRent (SMRT) Stock Plunges 21% as CEO Steps Down
July 30, 2024
SmartRent stock is falling on Tuesday as SMRT investors react to the resignation of the company's CEO and suspension of its 2024 outlook.
Via
InvestorPlace
Microsoft Office Outage: Microsoft Investigates Applications, Services Issue
July 30, 2024
A Microsoft Office outage has workers annoyed as its causing problems with them being able to use the company's services.
Via
InvestorPlace
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
July 30, 2024
Cassava Sciences has announced plans to extend trials for its Alzheimer’s treatment drug. This news isn't helping SAVA stock.
Via
InvestorPlace
Cassava Sciences Announces Expansion of Open-Label Extension Trials
July 30, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Get Your Money Out of These 3 Biotech Stocks Before the End of July
July 28, 2024
These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies.
Via
InvestorPlace
Nasdaq Up Triple Digits Amid Tech Resurgence
July 22, 2024
The Nasdaq Composite Index is up 190 points as Big Tech stages a comeback following last week's selloff.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials
July 22, 2024
Cassava Sciences' Phase 3 trials for Alzheimer's drug simufilam could change treatment standards. With trials costing millions, success could revolutionize care for millions. CEO emphasizes...
Via
Benzinga
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 22, 2024
Via
Benzinga
Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?
July 22, 2024
MIRA Pharmaceuticals stock is up on Monday after the company posted results from a pre-clinical trial of its novel oral ketamine analog.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.